Home

léléphant Traiteur Bermad desiree van der heijde Justice Nocif chauffeur

Désirée van der Heijde - Professor of Rheumatology - Leiden University  Medical Center | LinkedIn
Désirée van der Heijde - Professor of Rheumatology - Leiden University Medical Center | LinkedIn

Instrument development. ASDAS score with Desirée Van der Heijde - YouTube
Instrument development. ASDAS score with Desirée Van der Heijde - YouTube

ADARRC 2016 - Interview with Speaker: Désirée van der Heijde, MD, PhD, The  Netherlands - YouTube
ADARRC 2016 - Interview with Speaker: Désirée van der Heijde, MD, PhD, The Netherlands - YouTube

Profile - ASAS
Profile - ASAS

Joachim Sieper, Désirée van der Heijde, Maxime Dougados, L Steve  Brown,Frederic Lavie, Aileen L Pangan Ann Rheum Dis 2012;71: doi:  /annrheumdis ppt download
Joachim Sieper, Désirée van der Heijde, Maxime Dougados, L Steve Brown,Frederic Lavie, Aileen L Pangan Ann Rheum Dis 2012;71: doi: /annrheumdis ppt download

Désirée van der Heijden - Coach / Vertrouwenspersoon / Trainer / Acteur in  training - Deezs | Theater & Communicatie | LinkedIn
Désirée van der Heijden - Coach / Vertrouwenspersoon / Trainer / Acteur in training - Deezs | Theater & Communicatie | LinkedIn

Désirée van der Heijde, MD, PhD: Safety, Efficacy of Bimekizumab in  Ankylosing Spondyloarthritis
Désirée van der Heijde, MD, PhD: Safety, Efficacy of Bimekizumab in Ankylosing Spondyloarthritis

Researcher comment: The SELECT-AXIS 1 trial | Désirée van der Heijde -  YouTube
Researcher comment: The SELECT-AXIS 1 trial | Désirée van der Heijde - YouTube

Désirée van der Heijde: H-index & Awards - Academic Profile | Research.com
Désirée van der Heijde: H-index & Awards - Academic Profile | Research.com

Upadacitinib doubles ASAS 40 response vs. placebo in ankylosing spondylitis  | MDedge Rheumatology
Upadacitinib doubles ASAS 40 response vs. placebo in ankylosing spondylitis | MDedge Rheumatology

Désirée van der Heijde - Professor of Rheumatology - Leiden University  Medical Center | LinkedIn
Désirée van der Heijde - Professor of Rheumatology - Leiden University Medical Center | LinkedIn

Assessment in Ankylosing Spondylitis International Working  Group/Spondylitis Association of America recommendations for conducting  clinical trials in ankylosing spondylitis - van der Heijde - 2005 -  Arthritis & Rheumatism - Wiley Online Library
Assessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis - van der Heijde - 2005 - Arthritis & Rheumatism - Wiley Online Library

AxSpA eller ikke axSpA – det er spørsmålet
AxSpA eller ikke axSpA – det er spørsmålet

Updated axial SpA recommendations include IL-17 inhibitors | PM360
Updated axial SpA recommendations include IL-17 inhibitors | PM360

BE MOBILE 2: Bimekizumab in patients with active ankylosing spondylitis
BE MOBILE 2: Bimekizumab in patients with active ankylosing spondylitis

EULAR 2022 | The BE MOBILE 1 and 2 trials of bimekizumab in axSpA |  rheumatology.medicinematters.com
EULAR 2022 | The BE MOBILE 1 and 2 trials of bimekizumab in axSpA | rheumatology.medicinematters.com

Désirée van der Heijde - Leiden University
Désirée van der Heijde - Leiden University

PDF) Effects of baricitinib on radiographic progression of structural joint  damage at 1 year in patients with rheumatoid arthritis and an inadequate  response to conventional synthetic Disease-Modifying antirheumatic drugs
PDF) Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic Disease-Modifying antirheumatic drugs

Upadacitinib improves signs, symptoms in patients with active AS
Upadacitinib improves signs, symptoms in patients with active AS

Nieuwe voorzitter van de Ruggesteun bekend – Meer/Vandaag
Nieuwe voorzitter van de Ruggesteun bekend – Meer/Vandaag

Ook radio-dj Desiree van der Heiden naar PowNed - Planetzone
Ook radio-dj Desiree van der Heiden naar PowNed - Planetzone

EULAR 2020 - Speaker interview: 48 week data of Bimekizumab in r-axSpA -  YouTube
EULAR 2020 - Speaker interview: 48 week data of Bimekizumab in r-axSpA - YouTube

eMedEvents
eMedEvents

Prof.dr. D.M.F.M. (Désirée) van der Heijde (https://www.narcis.nl)
Prof.dr. D.M.F.M. (Désirée) van der Heijde (https://www.narcis.nl)

Eredoctoraat voor LUMC-hoogleraar Désirée van der Heijde | LUMC
Eredoctoraat voor LUMC-hoogleraar Désirée van der Heijde | LUMC